INTRODUCTION AND OBJECTIVES: Literature supports a bidirectional relationship between obstructive sleep apnea (OSA) and erection dysfunction (ED). The Eppworth Sleepiness Scale (ESS) is used to make a clinical diagnosis of OSA. The fragmentation of sleep and loss of REM sleep in OSA has been purported to lead to venous leak. No study has to date addressed the link between OSA and the presence of venous leak (VL).
METHODS: Patients who had ED, completed the international index of erectile function (IIEF) and underwent a penile duplex Doppler ultrasound constituted the study group. All completed the ESS. A score of >10 was used to define OSA and >16 severe OSA. All PDDU studies were done using a redosing injection agent schedule. Peak systolic velocity (PSV) >30cm/s and end diastolic velocity (EDV) <5cm/ s were considered normal. Comorbidity and erectile hemodynamics data were recorded. Data were compared between those with and without OSA. Pearson correlation coefficient was generated for he association between IIEF and ESS scores. Multivariable analysis was performed to define predictors of VL in the study cohort. Potential predictors included: patient age, diabetes, number of vascular comorbidities, history of radical prostatectomy (RP) and ESS.
RESULTS: 758 patients were included in the study. 91 (12%) men has an ESS>10 indicating OSA. Mean age: OSA 62AE13 vs non-OSA 64AE19 years (p¼0.03). Vascular comorbidity profile between the 2 groups was similar except for: coronary artery disease 17% vs 11% (p¼0.03); BMI 29AE6 vs 22AE1 (p¼0.015); RP history 16% vs 23% (0.02). The percentage of men with abnormal PSV: 26% vs 17% (p<0.01); abnormal EDV 17% vs 4% (p<0.01). There was a good correlation between IIEF erectile function domain score and ESS (r¼0.72). Predictors of the presence of VL are shown in the table.
CONCLUSIONS: There is a clear association between OSA and ED with greater degrees of OSA translating into poorer erectile function. OSA is a predictor of the presence of VL.
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MP84-18 ERECTILE DYSFUNCTION AFTER PROSTATIC RADIOTHERAPY: WHY MEASUREMENT MATTERS, A SYSTEMATIC REVIEW AND META-ANALYSIS Thomas Gaither*, Mohannad Awad, San Francisco, CA; E. Charles Osterberg, Austin, TX; Gregory Murphy, Isabel Allen, Albert Chang, San Francisco, CA; Raymond Rosen, Watertown, MA; Benjamin Breyer, San Francisco, CA INTRODUCTION AND OBJECTIVES: Rates of erectile dysfunction (ED) following the treatment of prostate cancer with radiotherapy (RT) vary. Pooled estimates of ED after RT will promote accurate patient counseling and shared decision-making. We systematically evaluated the development of ED in potent men after prostate RT.
METHODS: We performed a critical review of PubMed/Medline, Embase, the Cochrane Library, and Web of Science in April 2016 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. We identified prospective measures of ED before and after prostate RT. 278 abstracts were screened and 105 publications met the criteria for inclusion. Only men who were potent before RT were included in the analysis. We used metaregression to determine associations with ED.
RESULTS: In total, 17,057 men underwent brachytherapy (BT) (65%), 8,166 men underwent external beam radiation therapy (EBRT) (31%), and 1046 men underwent BT + EBRT (4%). The median followup time for all studies was 3 years (range 0.2-15 years). Seven common instruments were used to measure ED, with 23 different cutoffs for ED. The Sexual Health Inventory for Men (SHIM) was used in 31 studies (30%). Pooled estimates of SHIM-confirmed ED (<10-17), suggest the prevalence of ED after RT is 34% of men (95% confidence interval, CI 0.29-0.39) at 1 year, 39% (95% CI 0.33-0.44) at 2 years, 44% (95% CI 0.34-0.53) at 3 years, and 57% (95% CI 0.53-0.61) at 5.5 years. After controlling for median age in the study and percent of patients on androgen deprivation therapy, meta-regression showed that compared to BT alone, BT+EBRT increased the proportion of men with ED by 12.5% (95% CI 0.01-0.24). No differences were observed in the proportion of men with ED between studies of BT and EBRT. As the loss to follow-up increased by 10% within any of the studies, on average, the proportion of men with ED increased by 2.3% (95% CI 0.6-4.8).
CONCLUSIONS: Measurements of ED vary significantly in published series following RT. ED is common regardless of RT modality. Using the most objective measures, ED is found in approximately 50% of previously potent patients at 5 years. Loss to follow-up in studies may bias the results to overestimate ED.
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